Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist
Adult
Aged
Chelating Agents
/ chemistry
Female
Follow-Up Studies
Heterocyclic Compounds, 1-Ring
/ chemistry
Humans
Lutetium
/ therapeutic use
Male
Middle Aged
Neoplasm Metastasis
Neuroendocrine Tumors
/ metabolism
Octreotide
/ analogs & derivatives
Prognosis
Radioisotopes
/ therapeutic use
Radiopharmaceuticals
/ therapeutic use
Receptors, Somatostatin
/ antagonists & inhibitors
Young Adult
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 12 2019
01 12 2019
Historique:
received:
26
03
2019
revised:
12
06
2019
accepted:
06
08
2019
pubmed:
24
8
2019
medline:
22
9
2020
entrez:
24
8
2019
Statut:
ppublish
Résumé
Radiolabeled somatostatin receptor 2 (SSTR2) antagonists have shown higher tumor uptake and tumor-to-organ ratios than somatostatin agonists in preclinical models of neuroendocrine tumors (NETs). We performed a phase I study to evaluate the safety and efficacy of SSTR2 antagonist Twenty patients with advanced SSTR2-positive NETs were treated with Of 20 patients with NETs (one lung, seven small bowel, nine pancreatic, one gastric, one rectal, one kidney; mean prior treatments: three), six received one cycle of In this trial of heavily treated NETs, preliminary data are promising for the use of
Identifiants
pubmed: 31439583
pii: 1078-0432.CCR-19-1026
doi: 10.1158/1078-0432.CCR-19-1026
pmc: PMC8382090
mid: NIHMS1628035
doi:
Substances chimiques
Chelating Agents
0
Heterocyclic Compounds, 1-Ring
0
Radioisotopes
0
Radiopharmaceuticals
0
Receptors, Somatostatin
0
SSTR2 protein, human
0
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
1HTE449DGZ
Lutetium
5H0DOZ21UJ
Lutetium-177
BRH40Y9V1Q
Octreotide
RWM8CCW8GP
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6939-6947Subventions
Organisme : NCI NIH HHS
ID : K12 CA184746
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
J Pharmacol Exp Ther. 1999 Feb;288(2):729-34
pubmed: 9918582
Eur J Cancer. 2016 May;58:41-51
pubmed: 26943056
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):677-685
pubmed: 30374529
Br J Haematol. 2000 Jan;108(1):140-50
pubmed: 10651737
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):5-19
pubmed: 25273832
Cancer Biother Radiopharm. 2002 Aug;17(4):435-43
pubmed: 12396707
J Nucl Med. 2018 Jun;59(6):915-921
pubmed: 29191855
Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1138-46
pubmed: 19247653
Eur J Nucl Med. 1993 Aug;20(8):716-31
pubmed: 8404961
Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):453-63
pubmed: 26419852
N Engl J Med. 1986 Sep 11;315(11):663-6
pubmed: 2427948
J Clin Oncol. 2016 Feb 20;34(6):588-96
pubmed: 26712231
J Nucl Med. 2011 Sep;52(9):1412-7
pubmed: 21852357
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16436-41
pubmed: 17056720
J Clin Oncol. 2008 May 1;26(13):2124-30
pubmed: 18445841
J Clin Oncol. 2011 Jun 10;29(17):2416-23
pubmed: 21555692
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1802-11
pubmed: 27160225
J Nucl Med. 2013 Jan;54(1):33-41
pubmed: 23223392
Am J Anat. 1990 Mar;187(3):261-76
pubmed: 2321559
Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2125-35
pubmed: 21892623
N Engl J Med. 2014 Oct 16;371(16):1556-7
pubmed: 25317881
Exp Hematol. 2002 Feb;30(2):116-25
pubmed: 11823046
J Nucl Med. 2014 Aug;55(8):1248-52
pubmed: 24963127
Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S103-12
pubmed: 22388631
J Nucl Med. 2013 Nov;54(11):1857-61
pubmed: 24009272
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2426-2441
pubmed: 29785514
Br J Haematol. 1997 Sep;98(3):569-77
pubmed: 9332309
J Nucl Med. 2012 Sep;53(9):1481-9
pubmed: 22851637
J Nucl Med. 2005 Jun;46(6):1023-7
pubmed: 15937315
Semin Nucl Med. 2016 May;46(3):225-38
pubmed: 27067503
J Nucl Med. 2011 Dec;52(12):1886-90
pubmed: 22068898
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
Domest Anim Endocrinol. 1998 Sep;15(5):297-304
pubmed: 9785033